Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Prevalence of carbapenemases among high-level aminoglycoside-resistant Acinetobacter baumannii isolates in a university hospital in China.

Wang Y, Shen M, Yang J, Dai M, Chang Y, Zhang C, Luan G, Ling B, Jia X.

Exp Ther Med. 2016 Dec;12(6):3642-3652. doi: 10.3892/etm.2016.3828. Epub 2016 Oct 20.

2.

Variants of AbGRI3 carrying the armA gene in extensively antibiotic-resistant Acinetobacter baumannii from Singapore.

Blackwell GA, Holt KE, Bentley SD, Hsu LY, Hall RM.

J Antimicrob Chemother. 2017 Apr 1;72(4):1031-1039. doi: 10.1093/jac/dkw542.

3.

Acinetobacter baumannii: An Emerging and Important Pathogen.

Alsan M, Klompas M.

J Clin Outcomes Manag. 2010 Aug;17(8):363-369.

4.

Novel Aminoglycoside Resistance Transposons and Transposon-Derived Circular Forms Detected in Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.

Karah N, Dwibedi CK, Sjöström K, Edquist P, Johansson A, Wai SN, Uhlin BE.

Antimicrob Agents Chemother. 2016 Jan 11;60(3):1801-18. doi: 10.1128/AAC.02143-15.

5.

Genetic basis of high level aminoglycoside resistance in Acinetobacter baumannii from Beijing, China.

Nie L, Lv Y, Yuan M, Hu X, Nie T, Yang X, Li G, Pang J, Zhang J, Li C, Wang X, You X.

Acta Pharm Sin B. 2014 Aug;4(4):295-300. doi: 10.1016/j.apsb.2014.06.004. Epub 2014 Jul 15.

6.

Dissemination of clonal complex 2 Acinetobacter baumannii strains co-producing carbapenemases and 16S rRNA methylase ArmA in Vietnam.

Tada T, Miyoshi-Akiyama T, Shimada K, Nga TT, Thu le TA, Son NT, Ohmagari N, Kirikae T.

BMC Infect Dis. 2015 Oct 15;15:433. doi: 10.1186/s12879-015-1171-x.

7.

Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Doi Y, Murray GL, Peleg AY.

Semin Respir Crit Care Med. 2015 Feb;36(1):85-98. doi: 10.1055/s-0034-1398388. Epub 2015 Feb 2. Review.

8.

Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Viehman JA, Nguyen MH, Doi Y.

Drugs. 2014 Aug;74(12):1315-33. doi: 10.1007/s40265-014-0267-8. Review.

9.

Code blue: Acinetobacter baumannii, a nosocomial pathogen with a role in the oral cavity.

Richards AM, Abu Kwaik Y, Lamont RJ.

Mol Oral Microbiol. 2015 Feb;30(1):2-15. doi: 10.1111/omi.12072. Epub 2014 Sep 27. Review.

10.

Dissemination of 16S rRNA methylase ArmA-producing acinetobacter baumannii and emergence of OXA-72 carbapenemase coproducers in Japan.

Tada T, Miyoshi-Akiyama T, Shimada K, Shimojima M, Kirikae T.

Antimicrob Agents Chemother. 2014 May;58(5):2916-20. doi: 10.1128/AAC.01212-13. Epub 2014 Feb 18.

11.

Antimicrobial resistance determinants in Acinetobacter baumannii isolates taken from military treatment facilities.

Taitt CR, Leski TA, Stockelman MG, Craft DW, Zurawski DV, Kirkup BC, Vora GJ.

Antimicrob Agents Chemother. 2014;58(2):767-81. doi: 10.1128/AAC.01897-13. Epub 2013 Nov 18.

12.

Molecular characterization of NDM-1 producing Enterobacteriaceae isolates in Singapore hospitals.

Teo J, Ngan G, Balm M, Jureen R, Krishnan P, Lin R.

Western Pac Surveill Response J. 2012 Mar 29;3(1):19-24. doi: 10.5365/WPSAR.2011.2.4.010. Print 2012 Jan.

13.

Emergence of 16S rRNA methylase-producing Acinetobacter baumannii and Pseudomonas aeruginosa isolates in hospitals in Vietnam.

Tada T, Miyoshi-Akiyama T, Kato Y, Ohmagari N, Takeshita N, Hung NV, Phuong DM, Thu TA, Binh NG, Anh NQ, Nga TT, Truong PH, Xuan PT, Thu le TA, Son NT, Kirikae T.

BMC Infect Dis. 2013 May 30;13:251. doi: 10.1186/1471-2334-13-251.

14.

Evolution of a pathogen: a comparative genomics analysis identifies a genetic pathway to pathogenesis in Acinetobacter.

Sahl JW, Gillece JD, Schupp JM, Waddell VG, Driebe EM, Engelthaler DM, Keim P.

PLoS One. 2013;8(1):e54287. doi: 10.1371/journal.pone.0054287. Epub 2013 Jan 24.

15.

The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace.

Roca I, Espinal P, Vila-Farrés X, Vila J.

Front Microbiol. 2012 Apr 23;3:148. doi: 10.3389/fmicb.2012.00148. eCollection 2012.

16.

Identification of the aminoglycoside resistance determinants armA and rmtC among non-Typhi Salmonella isolates from humans in the United States.

Folster JP, Rickert R, Barzilay EJ, Whichard JM.

Antimicrob Agents Chemother. 2009 Oct;53(10):4563-4. doi: 10.1128/AAC.00656-09. Epub 2009 Jul 13. No abstract available.

17.

Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.

Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y.

Antimicrob Agents Chemother. 2008 Nov;52(11):3837-43. doi: 10.1128/AAC.00570-08. Epub 2008 Aug 25.

18.

Acinetobacter baumannii: emergence of a successful pathogen.

Peleg AY, Seifert H, Paterson DL.

Clin Microbiol Rev. 2008 Jul;21(3):538-82. doi: 10.1128/CMR.00058-07. Review.

19.

Detection of methyltransferases conferring high-level resistance to aminoglycosides in enterobacteriaceae from Europe, North America, and Latin America.

Fritsche TR, Castanheira M, Miller GH, Jones RN, Armstrong ES.

Antimicrob Agents Chemother. 2008 May;52(5):1843-5. doi: 10.1128/AAC.01477-07. Epub 2008 Mar 17.

20.

Escherichia coli isolate coproducing 16S rRNA Methylase and CTX-M-type extended-spectrum beta-lactamase isolated from an outpatient in the United States.

Doi Y, Adams-Haduch JM, Paterson DL.

Antimicrob Agents Chemother. 2008 Mar;52(3):1204-5. doi: 10.1128/AAC.01320-07. Epub 2008 Jan 14. No abstract available.

Supplemental Content

Support Center